Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities
Globe Newswire•01/10/2026•07:00 ET
0
Key Highlights
- ➤FHD-909 (FHTX) will not advance into clinical development expansion after Phase 1 review
- ➤SMARCA2 degrader program will not advance; Foghorn and Lilly anticipate no further collaboration activities
- ➤Workforce reduction of approximately 40% expected to extend cash runway into second half of 2029
- ➤Foghorn (FHTX) will prioritize proprietary EP300, oral immunology, CBP, and induced proximity programs
Expert Statements
Adrian Gottschalk, President and Chief Executive Officer of Foghorn Therapeutics
“While we are disappointed with the clinical results, we and Lilly developed a drug in FHD-909 that selectively hits the SMARCA2 target with a favorable safety profile at exposures that exceeded our preclinical targets. Unfortunately, the biology of the SMARCA2/4 synthetic lethality relationship has not translated into the level of efficacy required to further advance the program.”
Adrian Gottschalk, President and Chief Executive Officer of Foghorn Therapeutics
“We built Foghorn based on a demonstrated capability in designing drugs for challenging molecular targets, and we have leveraged this capability to build a proprietary pipeline. Today, we are committed to focusing our financial and developmental resources to advance these programs toward the clinic.”
Adrian Gottschalk, President and Chief Executive Officer of Foghorn Therapeutics
“Foghorn is reducing its workforce by approximately 40% and further aligning its operating structure resulting in cash to fund Foghorn’s priority programs into the second half of 2029.”
Adrian Gottschalk, President and Chief Executive Officer of Foghorn Therapeutics
“I would like to thank our partner Lilly for their support, as well as the patients, caregivers, investigators, study site staff, and all others who participated in and contributed to the FHD-909 clinical trial.”
* Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader program
* Company to focus resources on wholly owned pipeline, including a Selective EP300 degrader, a novel, oral immunology and inflammation program, a Selective CBP degrader and induced proximity platform
Get started
Create a free account to read the full story.